Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Cytosorbents (CTSO) EBIAT (2016 - 2025)

Cytosorbents (CTSO) has disclosed EBIAT for 14 consecutive years, with -$3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIAT fell 26.69% year-over-year to -$3.5 million, compared with a TTM value of -$11.9 million through Sep 2025, down 607.81%, and an annual FY2024 reading of -$16.5 million, up 43.6% over the prior year.
  • EBIAT was -$3.5 million for Q3 2025 at Cytosorbents, up from -$4.2 million in the prior quarter.
  • Across five years, EBIAT topped out at $15.3 million in Q4 2023 and bottomed at -$12.2 million in Q3 2022.
  • Average EBIAT over 5 years is -$4.7 million, with a median of -$4.7 million recorded in 2021.
  • The sharpest move saw EBIAT plummeted 1273.27% in 2021, then soared 2102.15% in 2023.
  • Year by year, EBIAT stood at -$9.3 million in 2021, then surged by 91.77% to -$766126.0 in 2022, then skyrocketed by 2102.15% to $15.3 million in 2023, then tumbled by 117.36% to -$2.7 million in 2024, then tumbled by 31.72% to -$3.5 million in 2025.
  • Business Quant data shows EBIAT for CTSO at -$3.5 million in Q3 2025, -$4.2 million in Q2 2025, and -$1.5 million in Q1 2025.